LQDA vs VRTX
Liquidia Corporation vs Vertex Pharmaceuticals — AI-powered side-by-side comparison
LQDA
Liquidia Corporation
68
Buy
VS
VRTX
Vertex Pharmaceuticals
66
Buy
| Metric | LQDA | VRTX |
|---|
| AI Score |
68
|
66
|
| Price |
$88.09
|
$529.70
|
| P/E Ratio |
368.26×
|
30.58×
|
| ROE |
-154.0%
|
21.2%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
91.8%
|
86.0%
|
| Debt / Equity |
1.70×
|
0.00×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
55.0
|
80.4
|
| Beta |
0.572
|
0.305
|
| Expected Upside |
—
|
+1.5%
|
AI Committee View
Current Innellis committee reasoning for LQDA versus VRTX.
LQDA leads by 2 points.
LQDA scores 68/100 (Buy) versus VRTX at 66/100 (Buy).
LQDA Committee View
67% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- ROE of 46.8% shows genuine earnings power backing the valuation — Value
- Revenue growing 1936.7% YoY -- genuine top-line momentum — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- P/E of 362.9 is expensive by classic value standards — Value
- Price-to-book of 12.9x prices in significant intangible value — Value
- MACD histogram negative -- bearish momentum — Technical
VRTX Committee View
50% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- ROE of 23.3% shows genuine earnings power backing the valuation — Value
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- P/E of 29.0 is moderate-to-rich — Value
- Price-to-book of 6.2x prices in significant intangible value — Value
- RSI at 80 is in overbought territory — Technical